ICER Cuts Price Recommendation for Paxlovid

The Institute for Clinical and Economic Review has issued a change to its suggested US price for Paxlovid, Pfizer’s antiviral drug for COVID-19, dropping it to between $563 and $906. The institute formerly recommended a price range of $3,600 to $5,800 for a round of treatment. The change was made based on new evidence regarding the drug’s ability to reduce hospitalizations among more widespread immunity to the virus in the nation.

According to Sriparna Roy and Michael Erman, “The drugmaker has not yet suggested what the price will be when it moves to a commercial market. Pfizer expects to roughly quadruple the price of its COVID-19 vaccine after the United States government’s current purchase program expires.”

To read more, click here.

(Source: Yahoo Finance, December 20^th, 2022)